NFKB1

NFKB1 Full Name

nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

NFKB1 Introduction

NFKB1 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) is one of the most extensively studied transcription factor genes in human biology and a central component of the NF-κB signaling pathway. The NFKB1 gene encodes the precursor protein p105, which undergoes proteasomal processing to generate the mature p50 subunit. Together with other NF-κB family members, p50 forms homo- or heterodimers that regulate the expression of hundreds of genes involved in immunity, inflammation, cell survival, stress responses, and tissue homeostasis. Because NF-κB signaling acts as a molecular bridge between extracellular stimuli and transcriptional responses, dysregulation of NFKB1 has profound biological consequences across multiple organ systems. Researchers and drug developers frequently investigate NFKB1 as a therapeutic target because it occupies a critical regulatory position at the intersection of immune activation, inflammatory signaling, and cancer development. Recent studies continue to highlight NFKB1 as a master regulator of cellular adaptation to environmental stress, infection, cytokine stimulation, and tissue injury, making it highly relevant for both basic research and translational medicine.

From a functional perspective, NFKB1 is essential for maintaining balanced immune responses. Activation of the canonical NF-κB pathway by stimuli such as tumor necrosis factor (TNF), interleukin-1 (IL-1), pathogen-associated molecular patterns, and antigen receptor signaling leads to the release and nuclear translocation of NF-κB complexes containing p50. Once in the nucleus, these complexes regulate genes involved in cytokine production, lymphocyte activation, apoptosis resistance, proliferation, and innate immune defense. NFKB1 also plays a crucial role in T-cell differentiation, B-cell maturation, macrophage activation, and the development of immunological memory. Importantly, NFKB1 does not function solely as an activator of inflammation; p50 homodimers can suppress excessive inflammatory responses and contribute to immune tolerance. This dual regulatory role helps explain why both increased and decreased NFKB1 activity can lead to pathological outcomes. Current evidence suggests that precise control of NFKB1 signaling is necessary for maintaining immune equilibrium, preventing chronic inflammation, and ensuring appropriate responses to infectious and environmental challenges.

The clinical significance of NFKB1 has expanded considerably in recent years due to growing evidence linking its dysregulation to cancer, autoimmune disorders, chronic inflammatory diseases, and primary immunodeficiency. Aberrant activation of NFKB1-driven signaling has been observed in numerous malignancies, including lymphoma, leukemia, breast cancer, colorectal cancer, lung cancer, and hepatocellular carcinoma, where it promotes tumor cell survival, angiogenesis, immune evasion, metastasis, and resistance to therapy. Conversely, loss-of-function mutations in NFKB1 represent one of the most common monogenic causes of primary antibody deficiency and are strongly associated with common variable immunodeficiency (CVID), recurrent infections, autoimmunity, and immune dysregulation syndromes. Emerging clinical studies further suggest that NFKB1 signaling contributes to the pathogenesis of rheumatoid arthritis, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, and other chronic inflammatory conditions. As a result, NFKB1 has become a high-priority target in drug discovery programs aimed at developing next-generation anti-inflammatory agents, immunomodulators, and cancer therapeutics. Its central role in coordinating immune and inflammatory networks continues to position NFKB1 as a critical biomarker and therapeutic target for precision medicine approaches.

Alternate Names for NFKB1

NFKB1; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; p50; KBF1; p105; EBP-1; NF-kB1; NFKB-p50; NFkappaB; NF-kappaB

• Immunohistochemistry Antibodies for Pathology

• 1.Song Z, et al.; NFKB1 as a key player in Tumor biology: from mechanisms to therapeutic implications. Cell Biol Toxicol. 2025, 41(1):29.
  2.Fathi N, et al.; Clinical, Immunological, and Genetic Features in Patients with NFKB1 and NFKB2 Mutations: a Systematic Review. J Clin Immunol. 2024, 44(7):160.